Rocket Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vanguard Portfolio Management has reported a beneficial ownership of 5.35% in Rocket Pharmaceuticals Inc. common stock as of June 30, 2026.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Rocket Pharmaceuticals Inc. following an internal realignment.
NASDAQ
Maverick Capital, Ltd. and its affiliates reported a 2.3% beneficial ownership stake in Rocket Pharmaceuticals, Inc. as of December 31, 2025.
NASDAQ
The Vanguard Group reported a 7.89% beneficial ownership stake in Rocket Pharmaceuticals Inc. as of December 31, 2025, alongside an internal realignment affecting future reporting.
NASDAQ
Maverick Capital and its affiliates have disclosed a passive beneficial ownership of 7.8% in Rocket Pharmaceuticals, Inc., totaling 8,363,813 shares.
NASDAQ
Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 0.93% in Rocket Pharmaceuticals, Inc.
NASDAQ
Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 6.7% in Rocket Pharmaceuticals, Inc. as of April 30, 2025.
NASDAQ
Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting beneficial ownership of 11.8% of Rocket Pharmaceuticals, Inc.'s common stock as of March 31, 2025.
NASDAQ
Maverick Capital, Ltd., along with its affiliates, has disclosed a 5.2% beneficial ownership stake in Rocket Pharmaceuticals, Inc., holding 5,547,175 shares of common stock.
NASDAQ
Wellington Management Group LLP and its affiliates have disclosed a 13.4% beneficial ownership stake in Rocket Pharmaceuticals, Inc. as of December 31, 2024, held for investment purposes.